Rudy Baumgartner has over 20 years of experience in pharmaceutical & biotechnology development. He has successfully undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, with their requisite face-to-face regulatory meetings, and has been awarded several biotechnology patents.
Dr. Baumgartner has served as Director of Clinical Research at Merck Research Laboratories, Rahway, NJ, working with both early and late stage assets. He then served as Vice President of Clinical Research and Therapeutic Area Head for Respiratory and Immunology of Sunovion Pharmaceuticals Inc. (previously Sepracor, Inc.) where he led the development and filing of multiple NDAs, including two approved by the FDA after the first cycle of review. He currently serves as Chief Medical Officer and Executive Vice President of Inotek Pharmaceuticals Corporation, responsible for all aspects of clinical development and medicals affairs.
Dr. Baumgartner received a B.S. and an M.D. from Pennsylvania State University and completed post-doctoral training at the University of Michigan, Johns Hopkins University and the National Institutes of Health (NIH).
Pharma & Biotech Development